臨床検査54巻3号

2010年03月発行

今月の主題 骨髄増殖性疾患 話題

骨髄増殖性疾患と血栓・止血

著者： 横山健次¹

所属機関： ¹慶應義塾大学医学部血液内科

ページ範囲：P.304 - P.308

1．はじめに

　骨髄増殖性疾患(myeloproliferative disorder；MPD)では血栓症の発症頻度が高くなることが報告されている．一方で皮下出血などの出血症状もしばしばみられる症状である．なかでも真性多血症(polycythemia vera；PV)，本態性血小板血症(essential thrombocythemia；ET)では血栓症は主要な死因であり，予後を左右する．本稿ではPV，ET患者を中心に，血栓症，出血症状の頻度，成因，治療法などに関して解説する．

参考文献

1) Elliott MA, Tefferi A：Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol　128：275-290, 2005

2) Marchioli R, Finazzi G, Landolfi R, et al：Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol　23：2224-2232, 2005

3) Carobbio A, Antonioli E, Guglielmelli P, et al：Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol　26：2732-2736, 2008

4) Michiels JJ, Berneman Z, Van Bockstaele D, et al：Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera：therapeutic implications. Semin Thromb Hemost　32：174-207, 2006

5) Sucker C, Michiels JJ, Zotz RB：Causes, Etiology and Diagnosis of Acquired von Willebrand Disease：A Prospective Diagnostic Workup to Establish the Most Effective Therapeutic Strategies. Acta Haematol　121：177-182, 2009

6) Michiels JJ, Berneman Z, Schroyens W, et al：The paradox of platelet activation and impaired function：Platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost　32：589-604, 2006

7) Cesar JM, de Miguel D, García Avello A, et al：Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100. Am J Clin Pathol　123：772-777, 2005

8) Dahabreh IJ, Zoi K, Giannouli S, et al：Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res　33：67-73, 2009

9) Lussana F, Caberlon S, Pagani C, et al：Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis：a systematic review. Thromb Res　124：409-417, 2009

10) Ziakas PD：Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia：measuring the uncertain. Haematologica　93：1412-1414, 2008

11) Carobbio A, Finazzi G, Antonioli E, et al：JAK2V617F allele burden and thrombosis：a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol　37：1016-1021, 2009

12) De Stefano V, Za T, Rossi E, et al：Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica　94：733-737, 2009

13) Marchetti M, Castoldi E, Spronk HM, et al：Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood　112：4061-4068, 2008

14) Carobbio A, Finazzi G, Antonioli E, et al：Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood　112：3135-3137, 2008

15) Carobbio A, Antonioli E, Guglielmelli P, et al：Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol　26：2732-2736, 2008

16) Barbui T, Carobbio A, Rambaldi A, et al：Perspectives on thrombosis in essential thrombocythemia and polycythemia vera：is leukocytosis a causative factor? Blood　114：759-763, 2009

17) Harrison CN, Campbell PJ, Buck G, et al：Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med　353：33-45, 2005

18) Santilli F, Romano M, Recchiuti A, et al：Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood　112：1085-1090, 2008

19) Trappenburg MC, van Schilfgaarde M, Marchetti M, et al：Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica　94：911-918, 2009

20) Landolfi R, Di Gennaro L：Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica　93：331-335, 2008